大二下病理淋巴.pptxVIP

Organs or tissues;;;;CD3;Benign pathological changes Indolent lymphoma in lymph node Aggressive lymphoma in lymph node Leukemia Anti-inflammatory treatment Anti-tumor therapy ;Lymphoid neoplasms（malignant lymphoma）; Lymphoma Hodgkin lymphoma , HL Non-Hodgkin lymphoma , NHL T and NK cell neoplasms B cell neoplasms ;Hodgkin Lymphoma , HL ( Hodgkin’s disease, HD) 霍奇金淋巴瘤/病;Epidemiology 10%-20% of all ML China 9.4％ Age and gender 双峰曲线：15－27岁 ＞50岁 Site： Lymph node: cervix etc extranode：spleen;Clinical features Primary: lymphadenopathy Systemic symptom B Symptom: fever，Night sweat， Weight loss，Itchy skin;;Classical RS cell;CD15 (+);;Clinical feature 40-70% of all HL Yong women Cervical，Supraclavicular and Mediastinal lymph node Good prognosis;Mixed cellularity HL, MCHL 混合细胞型;淋巴细胞消减型 Lymphocyte depletion HL, LDHL;Clinical feature: Young male：＜35岁，M:F＝2.5:1 Clinical feature：not obvious Prognosis ：10 years survival rate ＞80％ 2-6% of all HL 3-5% B cell lymphoma;Immunotype: CD30(-) CD15(-) B cell marker(+) Gene type: clonal Ig gene rearrangment;Non-Hodgkin lymphoma, NHL 非霍奇金淋巴瘤;Lymphoma versus Lymphoid leukemia;Origin precursor B cell/T cell Epidemiology B-LB ：children （＜10years），Leukaemia T-LB ：adolescent，Lymphoma ;Clinical feature High aggressive Bone marrow involvement Anemia,bleed,infection, etc Lymphadenopathy hepatomegaly splenomegaly;LB;Immunophenotype TdT 95％（+） T cell marker：CD3、CD2 B cell marker：CD19、CD20、CD79a Cytogenetic abnormality ＞90％ delete translocation hypodiploid hyperdiploid trisomy Treatment multiagent Chemotherapy ＞90％ complete remission(CR) 2/3 curable;Diffuse large B cell lymphoma, DLBCL弥漫性大B细胞淋巴瘤;origin: germinal center B-cell or active B-cell Epidemiology The commonest NHL: 30-40% of adult NHL in western countries, even higher in developing countries Age : the range is broad, the median age: 7th decade Sex : more common in males than females Aggressive, but